Odyssey Therapeutics, Inc. Common Stock
ODTXАкція
$18.47
Капіталізація$887.14M
P/E—
Див. дохідність—
Бета1.45
Графік ціни
Улюблені метрики
Ціна відносно S&P 500 (4 тиж.)7.90%
Загальна оцінка (VGM)81.94
Ринкова капіталізація$887.14M
Порівняння з галуззю — Біологічні препарати(180)
| Символ | Оцінка недооціненості | Оцінка зростання | Оцінка моментуму | Ціна |
|---|---|---|---|---|
ODTXOdyssey Therapeutics, Inc. Common Stock | — | A | B | $18.47 |
| AMGNAmgen Inc | C | C | C | $351.43 |
| GILDGilead Sciences Inc | C | B | C | $125.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $852.50 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $169.77 |
| BIIBBiogen Inc. Common Stock | B | D | B | $199.59 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $90.21 |
| MRNAModerna, Inc. Common Stock | D | B | A | $60.42 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $166.06 |
| EXELExelixis Inc | C | B | B | $52.87 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $347.63 |
Про акцію
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.